# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jack London (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET010-SYN
- Date: 2026-09-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe-Ibe, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review. **S**

## History of present illness

Mr. London has not had a drink since the evening two weeks ago when he sprained his ankle and drank two large whiskies for the pain; he talked that evening through with his counselor and has set a plan for pain and late afternoons. He takes naltrexone every morning without nausea. The ankle is much better with the brace and he has stopped the gel. He writes every morning and swims at the hour he used to take his first drink. He takes losartan 50 mg without dizziness; his home readings average 136/86. He is sleeping six hours. He has had no opioid or anti-inflammatory medicine. His hepatitis B, hepatitis C and HIV tests were negative. **S**

| Element | Detail |
|---|---|
| Alcohol | One evening two weeks ago; none since |
| PEth | 36 ng/mL, from 410 |
| Kidneys | Creatinine 1.96 mg/dL, eGFR 44; potassium 4.8; urine albumin 128 mg/g |
| Liver tests | AST 34, ALT 29, GGT 82 U/L |
| Vitamin D | 24 ng/mL |
| Mood | PHQ-9 5, item 9 scored 0 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better in the afternoons |
| Cardiovascular | Negative | No ankle swelling |
| Musculoskeletal | Positive | Right ankle slightly sore after a long walk |
| Psychiatric | Negative | Mood steadier; cravings in the late afternoon, less strong; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet once daily **S**
- Thiamine 100 mg oral tablet once daily **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen **S**
- Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines **S**
- Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 138/86 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 82.6 kg; BMI 27.6 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.8 mmol/L; Bicarbonate (total CO2): 23 mmol/L; Creatinine: 1.96 mg/dL (high); eGFR (CKD-EPI 2021): 44 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 128 mg/g (high); AST: 34 U/L; ALT: 29 U/L; GGT: 82 U/L (high); PEth (alcohol marker): 36 ng/mL (high); 25-hydroxyvitamin D: 24 ng/mL (low); PHQ-9: 5. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.6 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Bicarbonate (total CO2): 22 mmol/L at baseline, 23 mmol/L at this visit **S**
- Creatinine: 1.98 mg/dL (high) at baseline, 1.96 mg/dL (high) at this visit **S**
- eGFR (CKD-EPI 2021): 43 mL/min/1.73 m² (low) at baseline, 44 mL/min/1.73 m² (low) at this visit **S**
- Urine albumin-to-creatinine ratio: 240 mg/g (high) at baseline, 128 mg/g (high) at this visit **S**
- AST: 68 U/L (high) at baseline, 34 U/L at this visit **S**
- ALT: 41 U/L at baseline, 29 U/L at this visit **S**
- GGT: 186 U/L (high) at baseline, 82 U/L (high) at this visit **S**
- PEth (alcohol marker): 410 ng/mL (high) at baseline, 36 ng/mL (high) at this visit **S**
- PHQ-9: 9 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 138/86, pulse 78; weight 82.6 kg |
| Cardiovascular | Regular rhythm; no edema |
| Musculoskeletal | Right ankle: slight swelling, mild tenderness over the anterior talofibular ligament; walks normally |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3b A2** (N18.32). Stable: creatinine 1.96 mg/dL, eGFR 44; potassium 4.8 mmol/L. Urine albumin down from 240 to 128 mg/g on losartan 50 mg. 25-hydroxyvitamin D 24 ng/mL, insufficient, with a mildly high PTH. **S**
   - Losartan 100 mg daily from today; potassium and creatinine in four weeks.
   - Vitamin D3 25 micrograms daily.
2. **Hypertensive chronic kidney disease** (I12.9). 138/86, above target. **S**
   - Losartan to the maximum dose.
3. **Alcohol use disorder, severe, in early recovery** (F10.20). PEth 36 ng/mL fits the single evening of drinking he reported; liver tests near normal on naltrexone. Safety reviewed: no thoughts of suicide or self-harm, firearms locked, 988 card carried. **S**
   - Continue naltrexone and weekly counseling.
   - PEth at ten weeks.
4. **Right ankle sprain** (S93.401A). Healing well. **S**
   - Ankle exercises; brace for riding until fully healed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated device, average of readings) | Every visit | Completed today | 138/86 mmHg; home average 136/86 |
| Laboratory | Potassium and creatinine after starting or changing losartan or an SGLT2 inhibitor | Two to four weeks after each start or change | Completed today | Six weeks on losartan 50 mg: potassium 4.8 mmol/L, creatinine 1.96 mg/dL; recheck four weeks after today's increase |
| Laboratory | Creatinine with eGFR and urine albumin-to-creatinine ratio | G3b A2: twice a year, and at each medicine check | Completed today | eGFR 44; urine albumin 128 mg/g, down by about half |
| Laboratory | Electrolytes and bicarbonate | With each kidney test | Completed today | Sodium 140; bicarbonate 23 mmol/L |
| Laboratory | 25-hydroxyvitamin D | At baseline | Completed today | 24 ng/mL, insufficient; the test deferred from intake; vitamin D3 started |
| Medication safety | Medication reconciliation: no NSAIDs, kidney dosing, contrast safety | Every visit | Completed today | No oral NSAIDs; topical diclofenac for the sprain finished; acetaminophen within limits |
| Self-management | Lifestyle: sodium below 2 g a day, activity, diet, weight | Every visit | Completed today | Less salt; swimming most days |
| Survey | Drinking since the last visit (self-report) | Every visit | Completed today | One evening two weeks ago; none since |
| Laboratory | PEth | At baseline and every four to six weeks in early recovery | Completed today | 36 ng/mL, from 410 |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | At baseline, at four to six weeks, then every few months | Completed today | AST 34, ALT 29, GGT 82 U/L at four weeks of naltrexone |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | Every visit | Completed today | No nausea; no opioid; he declined to ask for one for the sprain |
| Referral | Addiction-focused counseling and mutual help | Weekly in early recovery | Completed today | Four sessions; a plan for pain and late afternoons |
| Survey | PHQ-9 and GAD-7 | At intake and at follow-up | Completed today | PHQ-9 5, from 9; item 9 scored 0 |
| Survey | Suicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked; 988 card carried |
| Self-management | Tobacco use and readiness to stop | Every visit | Completed today | About ten a day; will discuss at the preventive visit |

## Goal progress

- Find out how much kidney function is lost, how long it has been so, and why. Outcome by 2026-08-18: Chronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspected. **S**
- Stop drinking safely, and stay stopped. In progress; target 2027-02-02. **S**
- Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/80. In progress; target 2027-02-02. **S**
- Urine albumin down by at least 30 percent. In progress; target 2026-10-27. **S**
- No anti-inflammatory pain medicines, and pain controlled. In progress; target 2026-10-27. **S**
- Keep the morning writing hours. In progress; target 2026-10-27. **S**

## Medication changes

- Stopped: Losartan 50 mg oral tablet once daily **S**
- Started: Losartan 100 mg oral tablet once daily **S**
- Started: Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026), Aether Forge
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Preventive visit in two weeks. Ten-week review with potassium, creatinine and PEth. Counseling weekly. The clinic or 988 at any hour. **S**
- Next scheduled visit 2026-09-29: periodic adult preventive visit. **S**
